Evolving cancer resistance to anti-PD-1/PD-L1 antibodies in melanoma: Comprehensive insights with future prospects

This publication has 65 references indexed in Scilit:

• Acral melanoma: new insights into the immune and genomic landscape
  Neoplasia, 2023
• 1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study
  Annals of Oncology, 2023
• Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006
  Annals of Oncology, 2022
• Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy
  Annals of Oncology, 2022
• The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
  European Journal of Cancer, 2021
• Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
  Translational Oncology, 2021
• Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti‐PD‐1 monotherapy
  International Journal of Cancer, 2020
• A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
  Translational Oncology, 2019
• Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
  Cell, 2017
• Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma
  The Journal of Pathology, 2013